Next-Generation RET Inhibitor


Type of Alteration(s)
Point Mutations*
Alteration(s) of Interest
Key Considerations
NGS (Tissue)
  • Suitable for broad-based genomic profiling that includes targets in addition to RET
  • Selected assay should have full coverage of exons 8, 10, 11 and 13-16
Sanger Sequencing
  • Lower sensitivity than NGS for somatic alterations, thus more suitable for germline testing in MTC
  • Detection may require higher tumor content than PCR-based assays
  • Useful when tissue biopsy sample is limited/unavailable
  • Higher false negative rate than tissue-based NGS testing
Point mutations occur in MTC, and gene fusions occur in PTC and NSCLC
List is not exhaustive of all activating alterations
1. Mulligan LM. Nat Rev Cancer. 2014;14(3):173-186. 2. Drilon A et al. Nat Rev Clin Oncol 15:151-167, 2018

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.